Led by physician-scientist Tom Cahill, they form companies originating from academic discoveries in gene editing and regenerative medicine, presenting company-formation expertise, board track record, and a elevated formation-and-exit proven history.
Ranked by shared stages, industries, geography, cheque size and investor type. 400 related investors in the directory.
Nascent-stage investor spanning service-heavy care delivery and deep neuro/bio/AR frontier tech, delivering specialized neuro+AI+delivery expertise that bridges physical clinics and cutting-edge technologies. With a disciplined investment approach, the team drives value for both founders and investors.
Seed and early-phase investor that creates and funds biotech young companies, emphasizing company creation. Through targeted capital deployment, the fund plays an active role in the startup ecosystem.
Seed-stage investor in dual-use deep tech (six verticals) with an invite-only U.S. Service Academy alumni syndicate that co-invests, sources, vets deals, presents post-investment support, and runs a veteran-led track. The firm continues to build its presence across the venture capital landscape.
Invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. With a disciplined investment approach, the team drives value for both founders and investors.
Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. Through targeted capital deployment, the fund plays an active role in the startup ecosystem.
Backs early-phase life sciences businesses, often backing founders when they are no more than an idea.
